A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial

Hsu, Chiun; A. Hsiung, Chao; Su, Ih‐Jen; Hwang, Wei-Shou; Wang, Ming-Chung; Lin, Sheng-Fung; Lin, Tseng-Hsi; Hsiao, Hui-Hua; Young, Ji-Hsiung; Chang, Ming-Chih; Liao, Yu-Min; Li, Chi-Cheng; Wu, Hung-Bo; Tien, Hwei‐Fang; Chao, Tsu-Yi; Liu, Tsang‐Wu; Cheng, Ann‐Lii; Chen, Pei‐Jer

doi:10.1002/hep.22106

Public

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial

Published in Hepatology • Feb 7, 2008

Authors:

Chiun Hsu

Chao A. Hsiung

Ih‐Jen Su

Abstract

UNLABELLED: Lamivudine is effective to control hepatitis B virus (HBV) reactivation in HBV-carrying cancer patients who undergo chemotherapy, but the optimal treatment protocol remains undetermined. In this study, HBV carriers with newly diagnosed non-Hodgkin's lymphoma (NHL) who underwent chemother...

Subject

Lamivudine

Medicine

Chemotherapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!